← Back to patent-cliff list
Amisulpride Orally Disintegrating Tablets(Shanghai Zezheng Bio-pharma)
Tier C — Watch / tradeAmisulpride Orally Disintegrating Tablets(Shanghai Zezheng Bio-pharma)
-
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRD2, DRD3
Indications (approved)：Schizophrenia
Regional status
US
-
EU
-
China
Approved
2025-06-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amisulpride Orally Disintegrating Tablets(Shanghai Zezheng Bio-pharma)?
Approved indications include: Schizophrenia.
When does the Amisulpride Orally Disintegrating Tablets(Shanghai Zezheng Bio-pharma) patent expire?
No public expiry year is available for Amisulpride Orally Disintegrating Tablets(Shanghai Zezheng Bio-pharma) yet; this page updates once verified.
How do I get a quote for Amisulpride Orally Disintegrating Tablets(Shanghai Zezheng Bio-pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01